CIENCIASMEDICASNEWS: octubre 2026

sábado, 3 de octubre de 2026

FDA CDER’s Accelerating Rare Disease Cures Program

Revumenib + Chemotherapy in Newly Diagnosed AML With NPM1 Mutation: Phase 3 REVEAL-ND Study by CheckRare Staff| Published on: Sep 23, 2026

My name is Dr. Joshua Zeidner, and I’m a Professor of Medicine and Chief of Leukemia Research at the University of North Carolina Lineberger Cancer Center. I’m here today to raise awareness around an active global, phase 3, double-blind trial evaluating a combination regimen for participants with a specific type of acute myeloid leukemia or AML. https://checkrare.com/revumenib-chemotherapy-in-newly-diagnosed-aml-with-npm1-mutation-phase-3-reveal-nd-study/

FDA Approves New Therapies for MPS IIIA and SMA | The CheckRare Brief Ep 8 by CheckRare Staff| Published on: Sep 23, 2026

This week we discuss the FDA’s approval of Isembyld for SMA, the approval of a gene therapy for MPS IIIA, and the FDA’s Center for Devices and Radiological Health new Rare Disease Impact Initiative. https://checkrare.com/fda-approves-new-therapies-for-mps-iiia-and-sma-the-checkrare-brief-ep-8/

New Rare Disease Center of Excellence and FDA Advances in Rare Disease | The CheckRare Brief Ep 9 by CheckRare Staff| Published on: Sep 29, 2026

This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare disease. https://checkrare.com/new-rare-disease-center-of-excellence-and-fda-advances-in-rare-disease/

MOST READ IN Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261002

Novo bets big on Hengrui’s weight loss pill in $2.6B deal Pharma deals, regulatory updates, new treatments and more led the news this week. Brought to you byDDN editorial team

Novo bets big on Hengrui’s weight loss pill in $2.6B deal Pharma deals, regulatory updates, new treatments and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/novo-bets-big-on-hengrui-s-weight-loss-pill-in-2-6b-deal-17563 In an increasingly competitive oral GLP-1 market, Novo set its sights on Hengrui Pharma’s GLP-1/GIP dual receptor agonist that boasts the potential for once-weekly oral dosing. The company agreed to pay Hengrui $300 million up front for rights to the drug, HRS-1596, with milestone payments up to $2.6 billion. Currently, the drug is in Phase 1 trials in China to treat patients with type 2 diabetes and weight management. “Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation," said Martin Holst Lange, Executive Vice president, Research & Development and Chief Scientific Officer at Novo in the statement. – Allison Whitten

Raising the profile of NF1 and advocating for medical curiosity (+...)

https://rarerevolutionmagazine.com/digital_spotlights/nf1/ We are delighted to launch our newest RARE in Focus all about neurofibromatosis type 1(NF1). Huge thank you to our sponsors Childhood Tumour Trust who celebrate their 10th anniversary as a charity in 2026. Dive in to hear from Kirsten Samuel, Sheelagh Harwell, Ellie Day and Rakie Ayola. https://rarerevolutionmagazine.com/digitalspotlight/raising-the-profile-of-nf1-and-advocating-for-medical-curiosity/

Surprising culprit tied to 1 in 8 cancer cases worldwide, major study reveals By Melissa Rudy Fox News Published October 1, 2026 7:00am EDT (++...) +...

https://www.foxnews.com/health/surprising-culprit-tied-1-8-cancer-cases-worldwide-major-study-reveals?lid=i3pke6nuu72t Surprising culprit tied to 1 in 8 cancer cases worldwide, major study reveals 12 infections were tied to 2.3 million cancer cases in 2024, as oncologist shares prevention tips Melissa Rudy By Melissa Rudy Fox News Published October 1, 2026 7:00am EDT https://www.foxnews.com/health Lifestyle https://www.foxnews.com/lifestyle?lid=dao8o0gr8jb4

FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

The Role of Antidiabetic Drugs in Cutaneous Malignancies: An Evidence-Based Review (++)

The Role of Antidiabetic Drugs in Cutaneous Malignancies: An Evidence-Based Review Seanna Yang, MD; Nickoulet Babaei, MD; Dahyeon Kim, MD; Mireya Cervantes, MD; Minka Gill, MD; Jashin J. Wu, MD https://www.medscape.com/viewarticle/role-antidiabetic-drugs-cutaneous-malignancies-evidence-2026a100106u?ecd=wnl_edit_tpal_etid8756480&uac=148436CN&impID=8756480 Skin cancer is one of the more prevalent malignancies in patients with type 2 diabetes, and shared risk factors may increase susceptibility to both diseases. Antidiabetic medications may have potential roles in reducing the risk for cutaneous malignancies, while emerging evidence suggests possible therapeutic applications that warrant further investigation. We reviewed the association between type 2 diabetes and skin cancer and examined the potential effects of antidiabetic medications on cutaneous malignancies. A nonsystematic literature search was conducted, with supporting articles included for additional context. Current evidence suggests that metformin and thiazolidinediones may have chemopreventive and potential therapeutic effects in skin cancers, whereas the effects of other antidiabetic medications are less well studied. Certain agents also show potential as monotherapy or adjunctive therapy to standard cancer treatments. Further research is needed to determine whether antidiabetic medications can prevent or treat skin cancer in patients with type 2 diabetes. From Convolutional Neural Networks to Foundation Models: A New Era for Artificial Intelligence in Dermatology Rhea Singh, MD; Shari R. Lipner, MD, PhD https://www.medscape.com/viewarticle/convolutional-neural-networks-foundation-models-new-era-2026a100106y?ecd=wnl_edit_tpal_etid8756480&uac=148436CN&impID=8756480 The role that artificial intelligence (AI) should play in dermatology and what it means for dermatologists have transitioned from hypothetical questions to serious clinical issues.[1,2,3,4] Consider a 36-year-old woman with Fitzpatrick skin type IV who presents to her primary care provider with a slowly enlarging pigmented lesion with features that raise the physician’s concern for malignancy. During the clinical evaluation, an AI-based image analysis tool integrated into the electronic medical record analyzes a photograph of the lesion and independently flags it as high risk, supporting the clinician’s concern. The patient then is referred to dermatology, histopathology confirms invasive melanoma, and now the patient has a diagnosis.

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al.

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00450-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ims26&_hsenc=p2ANqtz--hzbEX0tUUh7eZZeRTeGq5sidbMN8haHsXcXt0bwOBrUsMk42dPY-eSMPHLiyE8mMxJPyqrv6Xd4GW6CSm8CJibJw9Qw&_hsmi=442274516&utm_source=hs_email

Reminder: explore our content from DGG 2026 (+++)

Understanding peripheral arterial disease in the current era Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00846-9/fulltext?dgcid=hubspot_email_conferencealerts_dgg26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9LABl5MLN-R5LAbyRCvxJHBIOFzMrcXRK40S-1KL6Fif8nVw5wO5NOfS5A7_nEiIbANMXbDn0jG2hfNzgYgAXIbh1xrQ&_hsmi=442274702&utm_source=hs_email Understanding peripheral arterial disease in the current era Prof Christian-Alexander Behrendt, MDa,b Send email to behrendt@hamburg.de ∙ Prof Lars Norgren, PhDc ∙ Chalotte W Nicolajsen, PhDd ∙ Prof Janet T Powell, PhDe,* ∙ Prof Vivienne Chuter, PhDf ∙ Prem Chand Gupta, MSg ∙ et al. Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment Free with registration until Oct 4th, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00845-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_dgg26&_hsenc=p2ANqtz-8FtTc2-27U5liSgQ9Pb3rtxd6P9gCgE1SaGfzeLSRlY-8ZHSdYoyNsk-vwvmoKZfgdNASLk1Eb2vhAqwp0jEIVbetriw&_hsmi=442274702&utm_source=hs_email Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment Riikka Tulamo, PhDa Send email to riikka.tulamo@hus.fi ∙ Prof Andrew Bradbury, FRCSb ∙ Caitlin W Hicks, MDc ∙ Prof Anders Gottsäter, PhDd ∙ Prem Chand Gupta, MSe ∙ Prof Ulrich Rother, MDf ∙ et al. Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00847-0/fulltext?dgcid=hubspot_email_conferencealerts_dgg26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--B1JEW5oYB1VESfaczmEzX7IICmcVTeDK8O3zeHkXzJg_OjZEx40d_waiClJpMu9SXg2FUSYjHLGudPcubaWEl8Mf4rg&_hsmi=442274702&utm_source=hs_email Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead Prof Jonathan Golledge, MChira,b,c Send email to jonathan.golledge@jcu.edu.au ∙ Prof Mette Søgaard, PhDd,e ∙ Prof Mikael Svensson, PhDf ∙ Prem Chand Gupta, MSg ∙ Prof Sigrid Nikol, PhDh,i ∙ Prof Paulo Eduardo Ocke Reis, PhDj ∙ et al.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_wcc26&_hsenc=p2ANqtz-8Icy3oe1_nFvpREUVOnm6jrEYqE23yRz93q0vv438UInrVq8Tc-FDH7wshJAlwkLfbCRfvLzgf1nmpwNS9nfT0BFB8rA&_hsmi=442274309&utm_source=hs_email

Second Indication for Aqneursa in Ataxia Telangiectasia by Madaline Spencer| Published on: Sep 22, 2026

https://checkrare.com/second-indication-for-aqneursa-in-ataxia-telangiectasia/ The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine) for oral suspension to treat ataxia in patients with ataxia-telangiectasia who weigh at least 33 pounds (15 kg). It is the first treatment approved for this rare condition. Ataxia telangiectasia is a rare genetic disorder that affects the nervous system, the immune system, and many other parts of the body. The condition is typically characterized by early childhood onset of cerebellar ataxia, oculomotor apraxia, telangiectasias, choreoathetosis, a weakened immune system with frequent infections, and an increased risk of cancers such as leukemia and lymphoma. It is caused by changes in the ATM gene located on chromosome 11q22-23.

FDA Approves Gazyva (Obinutuzumab) for Treatment of Childhood-Onset Idiopathic Nephrotic Syndrome by Madaline Spencer| Published on: Oct 1, 2026

https://checkrare.com/fda-approves-gazyva-obinutuzumab-for-treatment-of-childhood-onset-idiopathic-nephrotic-syndrome/ The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. INS is a rare, autoimmune kidney disease characterized by unpredictable relapses that cause fatigue, swelling, weight gain and increased susceptibility to infections and clotting, as well as anxiety, depression and reduced self-esteem, brought on by the fear of relapse and social isolation. It is usually diagnosed in early childhood and is the most common form of primary glomerular disease in children.

Rett Syndrome Awareness Month by CheckRare Staff| Published on: Oct 1, 2026

https://checkrare.com/rett-syndrome-awareness-month/ Rett syndrome is a neurodevelopmental condition that primarily affects girls. People with the disease appear to have normal psychomotor development during the first 6 to 18 months of life before developing severe problems with language and communication, learning, coordination, and other brain functions. Additional signs and symptoms may include repetitive, stereotypic hand movements, fits of screaming and inconsolable crying, autistic features, panic-like attacks, teeth grinding, episodic apnea and/or hyperpnea, gait ataxia and apraxia, tremors, seizures, and slowed head growth. Classic Rett syndrome is most commonly caused by genetic changes in the MECP2 gene.

viernes, 2 de octubre de 2026

Understanding peripheral arterial disease in the current era (++)

Understanding peripheral arterial disease in the current era Prof Christian-Alexander Behrendt, MDa,b Send email to behrendt@hamburg.de ∙ Prof Lars Norgren, PhDc ∙ Chalotte W Nicolajsen, PhDd ∙ Prof Janet T Powell, PhDe,* ∙ Prof Vivienne Chuter, PhDf ∙ Prem Chand Gupta, MSg ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00846-9/fulltext?dgcid=raven_jbs_etoc_feature_lancet NHS campaigners target Palantir Talha Burki https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01982-3/abstract?dgcid=raven_jbs_etoc_feature_lancet

Peripheral arterial disease: counting what matters The Lancet (+...)

Peripheral arterial disease: counting what matters The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10562/PIIS0140-6736(26)X2037-2

Read our latest conference content (+++++) (++) (++) Explore our content from the 2026 EASD Annual Meeting

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al.

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Prof Sheraz Yaqub, MD PhDa,b Send email to sheraz.yaqub@medisin.uio.no ∙ Morten Valberg, PhDc ∙ Bjørn Atle Bjørnbeth, MD PhDa ∙ Jon-Helge Angelsen, MD PhDd,e ∙ Kristoffer Watten Brudvik, MD PhDa ∙ Ina Andrassy Eilertsen, PhDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00260-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ihpba26&_hsenc=p2ANqtz-8dpguG_cBBSA_NrbdyonXHBGmFr4osFo9lOq9RKriYu6U80R_1teTApjRFgVKd2oNEAiPxK_XfhJjrHNxXwhbvvJ3HDw&_hsmi=442102189&utm_source=hs_email

Whole genome sequencing for Klebsiella pneumoniae in the Tunisian antimicrobial resistance surveillance system: micro-costing, pragmatic cost-effectiveness, and budget impact evaluation

Whole genome sequencing for Klebsiella pneumoniae in the Tunisian antimicrobial resistance surveillance system: micro-costing, pragmatic cost-effectiveness, and budget impact evaluation Dana Itania Send email to dana.itani@alumni.lshtm.ac.uk ∙ Kasim Allelb,c ∙ Sanaa Farjanid,k ∙ Hanen Smaouie ∙ Meriam Zribif ∙ Lamia Thabetg ∙ et al. https://www.thelancet.com/journals/laneme/article/PIIS3050-5054(26)00005-0/fulltext?dgcid=hubspot_email_conferencealerts_gmi16&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_F4pzVHPhNJPBhxMDosRxh5zyeuYmYSgVktHlyZqMbqWbyYSKaftmKQMOrEiDcTdkLOvdoo-8E6i-qM9YISTGsPizTvg&_hsmi=442103080&utm_source=hs_email

Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD

https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1

The Lung Cancer Landscape: Covering Key Advances in NSCLC and SCLC Authors: Heather Wakelee, MD, FASCO; Christina S. Baik, MD, MPH; Misty D. Shields, MD, PhD

https://www.medscape.org/viewarticle/lung-cancer-landscape-covering-key-advances-nsclc-and-sclc-2026a1000zw1?page=1

DLBCL Redefined: A Case-Based Journey From Frontline Breakthroughs to Relapsed/Refractory Frontiers Authors: Gilles Salles, MD, PhD; Ayushi Chauhan, MD; Kami Maddocks, MD

https://www.medscape.org/viewarticle/dlbcl-redefined-case-based-journey-frontline-breakthroughs-2026a1000zyn?page=1

World Stage Insights: Global Advances in Targeted NSCLC Therapies Authors: Joshua Sabari, MD; Kathryn C. Arbour, MD; Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/world-stage-insights-global-advances-targeted-nsclc-2026a10010de?page=1

Lower-Risk MDS: Translating Evidence Into Community-Based Practice Authors: Hetty Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Amer M. Zeidan, MBBS, MHS

https://www.medscape.org/viewarticle/lower-risk-mds-translating-evidence-community-based-practice-2026a100106z?page=1

Can CT Urography and Cytology Replace Ureteroscopy for Surveillance After Kidney-Sparing Surgery in Upper Tract Urothelial Cancer?

https://www.medscape.com/viewarticle/can-ct-urography-and-cytology-replace-ureteroscopy-2026a10010lg?src= A combined CT urography and urinary cytology surveillance strategy in patients managed with endoscopic kidney-sparing surgery for upper tract urothelial carcinoma would have avoided more than two thirds of ureteroscopies but missed nearly two thirds of recurrences.

Few Women Consistently Use Endocrine Therapy Post-Lumpectomy

Few Women Consistently Use Endocrine Therapy Post-Lumpectomy Many women who undergo lumpectomy for early-stage breast cancer do not adhere to endocrine therapy long term, and those who skip radiotherapy may be a particularly vulnerable group. An analysis of insurance claims found that less than 30% of patients consistently adhered to endocrine therapythroughout all 5 recommended years. And two groups were especially likely to have substantial lapses in adherence: patients younger than 60 years and those who did not receive radiotherapy post-surgery. https://www.medscape.com/viewarticle/few-women-consistently-use-endocrine-therapy-post-lumpectomy-2026a10010oq?src= American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Pancreatic Cancer: Is SBRT or ChemoRT Better Before Surgery? M. Alexander Otto, MMSc-PA

https://www.medscape.com/viewarticle/pancreatic-cancer-sbrt-or-chemort-better-before-surgery-2026a10010o7?src= BOSTON — What type of neoadjuvant therapy is best for patients with resectable, borderline, or locally advanced pancreatic ductal adenocarcinoma (PDAC)? While neoadjuvant therapy has become more common, the optimal type and duration of treatment remain unclear, explained William Hall, MD, radiation oncologist at the Medical College of Wisconsin in Milwaukee. American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Nearly 1 in 8 Cancers Worldwide Caused by Infections Frederik Joelving

https://www.medscape.com/viewarticle/nearly-1-8-cancers-worldwide-caused-infections-2026a10010mx?src= About 2.3 million cancer diagnoses in 2024, or 12% of all cases globally, were caused by infections, according to a new study from the Interna ti onal Agency for Research on Cancer (IARC). Those cancers were attributable to 12 infectious agents known to be carcinogenic to humans. At the top of list were Helicobacter pylori and human papillomavirus (HPV), which together caused roughly 1.5 million cancers worldwide in 2024. H. pylori is the primary cause of gastric cancers globally, while certain strains of HPV cause virtually all cervical cancers and contribute to several other cancer types. Meanwhile, an estimated 360,000 cancer cases were attributed to hepatitis B virus and 160,000 to hepatitis C. And in what researchers called a notable finding, Epstein-Barr virus (EBV) accounted for roughly 260,000 cancer diagnoses in 2024.

Shorter-Course Radiotherapy Is Safe Option for High-Risk Breast Cancer Dawn Attride

https://www.medscape.com/viewarticle/shorter-course-radiotherapy-safe-option-high-risk-breast-2026a10010pm?src= Locoregional recurrence remained low over 10 years in patients with high-risk breast cancer who received shorter courses of radiotherapy after mastectomy in a phase 3 trial. Among postmastectomy patients requiring regional nodal irradiation, hypofractionated radiotherapy and conventional fractionated radiotherapy showed comparable cumulative incidence of locoregional recurrence at 5 years (9.6% vs 8.6%), the primary endpoint of the trial. There were no significant differences in survival outcomes or increases in severe late adverse effects. American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Intralesional RNA Immunotherapy Shows Promise for BCC

https://www.medscape.com/viewarticle/intralesional-rna-immunotherapy-shows-promise-bcc-2026a10010qi?src= VIENNA — More than half of patients with high-risk basal cell carcinoma (BCC) of the head and neck (18 of 32; 56%) had no visible tumor and no viable tumor on pathology 24 weeks after three intralesional injections of the experimental RNA immunotherapy BO-112, a phase 2b trial found. The complete response rate was slightly higher among the subgroup of patients with high-risk facial lesions, at 62% (16 of 26). https://www.medscape.com/c25/p14/european-academy-dermatology-and-venereology-eadv-2026-2026a1000xdj European Academy of Dermatology and Venereology (EADV) 2026 Congress

One Target, Five Antibodies: Why Anti-CD20 Mechanism Now Decides Outcomes in Lymphoma, MS, and Lupus Nephritis

https://www.medscape.com/c99/p10/one-target-five-antibodies-why-anti-cd20-mechanism-now-2026a10010oz?src= In October 2025, obinutuzumab became the first anti-CD20 monoclonal antibody to win an FDA indication for active lupus nephritis. Gazyva PI Two earlier placebo-controlled trials of the Type I antibodies rituximab and ocrelizumab in proliferative lupus nephritis had failed to show a statistically significant benefit on renal response. Furie ARD 2022Readers should be aware of an important safety context behind the ocrelizumab trial (BELONG): it was not simply neutral on efficacy, it was stopped early by the sponsor specifically because of a safety signal, an imbalance in serious and opportunistic infections in ocrelizumab-treated patients compared with placebo, most notably a 3.2% vs 0.8% rate of serious opportunistic infections in the 400 mg ocrelizumab arm. Mysler Arthritis Rheum 2013

New Cancer Drugs: Can Care Keep Up With Innovation? Harald Müller-Huesmann, MD

https://www.medscape.com/viewarticle/new-cancer-drugs-can-care-keep-innovation-2026a10010g7?src= Breast cancer remains a major driver of innovation in oncology, not least because it is one of the largest treatment markets and is also the most common diagnosis I encounter in my daily rehabilitation work. In addition to the established oral selective estrogen receptor degrader (SERD) elacestrant, two additional oral SERDs, camizestrant and imlunestrant, are now available for patients with ESR1 mutations. Imlunestrant is approved as monotherapy for adults with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation after progression on endocrine therapy.

How Scientists Finally Cracked RAS in Pancreatic Cancer Lisa Marshall

https://www.medscape.com/viewarticle/how-scientists-finally-cracked-ras-pancreatic-cancer-2026a10010ok It’s not often that slide presentations at medical conferences prompt thousands of audience members to leap to their feet, some embracing or openly weeping. But that’s what happened when pancreatic cancer specialist Brian Wolpin, MD, MPH, began to present his latest research at the American Society of Clinical Oncology meeting in Chicago this past May. A hush fell over the crowd. Wolpin began to report “a statistically significant improvement in overall survival…” Before he could finish his sentence, the audience erupted.

New Video Game Reveals How Kids With Autism Make Decisions

https://www.medscape.com/viewarticle/new-video-game-reveals-how-kids-autism-make-decisions-2026a10010g4?ecd=WNL_trdalrt_pos1_ous_261002_etid8753650&uac=148436CN&impID=8753650

jueves, 1 de octubre de 2026

How Will Personalized Care Shape Microbiome Therapies? Clara Simón

https://www.medscape.com/viewarticle/how-will-personalized-care-shape-microbiome-therapies-2026a100109z?ecd=WNL_trdalrt_pos1_ous_261001_etid8750402&uac=148436CN&impID=8750402 Changes in the gut microbiota are associated with inflammatory diseases, prompting researchers to investigate whether targeted interventions can help manage these conditions. However, evidence suggests that microbiota-based therapies may need to be tailored to individual patients rather than applied through a one-size-fits-all approach.

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_260930-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

Future proofing food systems The Lancet Planetary Health (+...)

Future proofing food systems The Lancet Planetary Health https://www.thelancet.com/journals/lanplh/issue/vol10no8/PIIS2542-5196(26)X2008-3

Turkish Government crackdown on HIV and LGBTQ+ groups The Lancet HIV (+...)

Turkish Government crackdown on HIV and LGBTQ+ groups The Lancet HIV https://www.thelancet.com/journals/lanhiv/issue/vol13no10/PIIS2352-3018(26)X2009-4

DTAC Bulletin: Managing Chronic Disease During Disasters

Managing Chronic Disease During Disasters According to the Centers for Disease Control and Prevention (CDC), 75 percent of U.S. adults have at least one chronic disease, such as heart disease, cancer, diabetes, epilepsy, or kidney disease.1 Because chronic conditions are so widespread, it is critical that people with chronic conditions, their families and caregivers, and emergency management personnel develop plans for managing these conditions during disasters. Explore the resources below to learn more about how you or your loved ones with chronic diseases can prepare for disasters. Federal Guidelines for Opioid Treatment Programs Opioid use disorder (OUD) is a chronic medical condition for which uninterrupted access to treatment is especially important during disasters. The Federal Guidelines for Opioid Treatment Programs (pages 21–22) offer recommendations to help maintain continuity of care, access to medications, patient communication, and support for individuals affected by transportation or mobility challenges during emergencies. After the Storm: Managing Chronic Conditions after a Natural Disaster https://www.cdc.gov/natural-disasters/media/pdfs/2024/managing-chronic-conditions-after-natural-disaster-508.pdf?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 This CDC tip sheet discusses what to do following a disaster for those with a chronic condition. Conditions covered include Alzheimer’s disease, cancer, diabetes, heart disease, and mental health conditions. This resource also includes QR codes to materials with further information. Planning for Emergencies: A Guide for People with Kidney Disease https://nkfm.org/wp-content/uploads/2024/02/NKF-Planning-for-Emergencies-A-Guide-for-People-with-CKD.pdf?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 More than 35.5 million adults in the United States have chronic kidney disease.2 This guide, provided by the National Kidney Foundation, offers information and forms that people with chronic kidney disease and their loved ones can use to prepare for disasters. The guide provides general preparedness tips for people with kidney disease, steps to take after a natural disaster, and diet recommendations for people who use dialysis to manage chronic kidney disease and cannot access dialysis services during or after a disaster. Emergency Preparedness for Older Adults and People With Disabilities The Administration for Community Living (ACL) designed this poster to help people prepare for emergencies. It highlights how to prepare electric medical devices for power outages, the importance of creating a network of support, and what to include in an emergency preparedness kit. ACL also offers a medical information card that can be printed and included in emergency preparedness kits for those living with chronic illnesses or disabilities. Questions About the SAMHSA DTAC Bulletin? The SAMHSA DTAC Bulletin is a monthly newsletter used to share updates in the field, post upcoming activities, and highlight new resources. For more information, please contact: Anne Genet Reim, M.P.H. 202–713–7866 anne.reim@samhsa.hhs.gov CDR Katie Hager, M.S., B.S.N., RN 240–276–1268 katie.hager@samhsa.hhs.gov About Chronic Diseases https://www.cdc.gov/chronic-disease/about/index.html?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 Fast Facts: Health and Economic Costs of Chronic Conditions https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245

Why stem cell-like T cells are shaping the next generation of CAR-T therapies A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses. Written byAndrea Corona

Why stem cell-like T cells are shaping the next generation of CAR-T therapies A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses. Written byAndrea Corona https://www.drugdiscoverynews.com/why-stem-cell-like-t-cells-are-shaping-the-next-generation-of-car-t-therapies-17245?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--efgamE1Gmy4uyIgUR7nBO6A5uyXHmPHWqmd3uptexQwEX84SHCBeLKx-ySiqNdpXSAlX7LT9bPRyGfKirF8qTy_KRgg&_hsmi=442044179&utm_content=442044179&utm_source=hs_email CAR-T cell therapy has transformed outcomes in certain blood cancers, but it has always carried the fundamental vulnerability that the cells that make it work do not always last. Infused T cells can expand, contract, and exhaust, in turn leaving patients who initially responded without the sustained immune pressure needed to prevent relapse. Understanding why some patients maintain durable remissions while others do not has pointed the field toward a rare immune cell subset that may hold the answer. Stem cell-like memory T cells, known as Tscm cells, occupy a unique position in the T cell differentiation hierarchy. Phenotypically resembling naive T cells, they are in fact the least differentiated of the memory T cell subpopulations, sitting at the apex of the memory hierarchy as progenitors capable of giving rise to all downstream memory and effector subsets. Their defining properties, such as self-renewal, long-term persistence, and potent antitumor activity, make them a compelling foundation for cell therapies that need to outlast the tumor.

Stem cell discovery opens nonsurgical era for lumbar spinal stenosis Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments. Written byPriyom Bose

Stem cell discovery opens nonsurgical era for lumbar spinal stenosis Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments. Written byPriyom Bose https://www.drugdiscoverynews.com/stem-cell-discovery-opens-nonsurgical-era-for-lumbar-spinal-stenosis-17561 When a thin ligament in the spine thickens and bulges into the central canal, it compresses spinal nerves and leads to pain, numbness, and mobility issues. That’s what happens in lumbar spinal stenosis (LSS), which affects an estimated 103 million people worldwide.

Resources for Your Rural Maternal Health Network

Resources for Your Rural Maternal Health Network Tools and guidance to help build networks, implement innovative strategies, and use data to improve maternal health outcomes in rural communities https://ruralmaternaldata.org/?utm_medium=email&utm_source=govdelivery The HRSA-funded Rural Maternal Health Data Support program launched a new tool for creating customized maternal health profiles for counties across all 50 states and Washington, DC. Users can select one or more counties to explore combined indicators on demographics, health care provider capacity, maternal health outcomes, and hospital obstetric services. Profiles include state and national comparisons, county-level maps of obstetric service availability, and full source citations to support maternal health planning and analysis.

Free Continuing Education Credits for Healthcare Professionals

Free Continuing Education Credits for Healthcare Professionals Healthcare providers can now earn free continuing education (CE) credits while learning how to recognize and address the harms associated with screen use in children and adolescents. https://www.hhs.gov/surgeongeneral/reports-and-publications/screen-use-harms/index.html?utm_medium=email&utm_source=govdelivery#free-continuing-education Healthcare providers can now earn free continuing education (CE) credits while learning to recognize and address harms associated with screen use among children and adolescents. The Office of the Surgeon General, in partnership with the American College of Preventive Medicine (ACPM), offers 1.5 AMA Category 1 Credits™ for the Screen Use Advisory and 1 credit for the accompanying Toolkit. Eligible providers can register with ACPM to earn credits while accessing evidence-based guidance and practical resources.

Downloadable Resource for Parents: The Magic TabletThe Magic

Downloadable Resource for Parents: The Magic TabletThe Magic Tablet is designed as a companion to the Surgeon General’s advisory on the harms of screen use, encouraging children and adolescents to get off screens and live real life. https://www.hhs.gov/surgeongeneral/reports-and-publications/screen-use-harms/index.html?utm_medium=email&utm_source=govdelivery#magic-tablet

Webinar October 13, 12:00 – 1:00 pm ET Strengthening Rural Behavioral Health Care Access Through a Community-Based Workforce

https://www.chcs.org/resource/strengthening-rural-behavioral-health-care-access-through-a-community-based-workforce/?utm_campaign=017935fc37-Access+Rural+BH+Webinar_9%2F9%2F2026&utm_medium=email&utm_source=govdelivery&utm_term=0_-017935fc37-493395962 The Center for Health Care Strategies (CHCS) will host a webinar on Tuesday, October 13, 2026, at 12:00 PM ET, highlighting community-based workforce models expanding rural behavioral health care in Georgia, North Carolina, and Tennessee. Speakers will discuss integrating peer support specialists, community health workers, and community paramedics into care teams, with practical insights on program design, recruitment, sustainability, and implementation. The webinar draws on provider experiences and findings from an upcoming CHCS brief.

Maternal Suicide Prevention Strategies October 6, 2026 10:30 am - 11:30 am Pacific Time

https://secure.everyaction.com/7TlpBtZVi0mZVATbB6Lt0g2?ceid=24196946&emci=fcbb1e8e-a7a8-f111-9b33-0022482a933b&emdi=084af609-cbab-f111-9b33-0022482a933b&utm_medium=email&utm_source=govdelivery Maternal Suicide Prevention Strategies This Policy Center for Maternal Health webinar invites obstetric providers, maternal mental health specialists, suicide prevention leaders, and perinatal psychiatrists to advance evidence-based maternal suicide prevention strategies and improve crisis response systems for pregnant and postpartum individuals. The session will address the role of depression as an indicator of suicide risk, and treatments, including a discussion about medications and black box warnings, among other topics. Held Tuesday, October 6, 2026, at 12:30 PM ET.

National Lead Poisoning Prevention Week

https://www.epa.gov/lead/national-lead-poisoning-prevention-week?utm_medium=email&utm_source=govdelivery National Lead Poisoning Prevention Week (NLPPW) takes place October 25–31 during Children’s Health Month. This year’s theme, “Keep Kids Safe From Lead,” focuses on raising awareness and educating communities about preventing childhood lead exposure. NLPPW brings together individuals, organizations, industry, and state, tribal, territorial, and local governments. The CDC, EPA, and HUD have collaborated to provide comprehensive resources that help communities increase awareness, support prevention efforts, and protect children from the harmful effects of lead exposure.

Breast Cancer Awareness Month (+...)

https://www.cdc.gov/breast-cancer/?utm_medium=email&utm_source=govdelivery Observed each October, Breast Cancer Awareness Month promotes awareness of breast cancer and the importance of early detection. Breast cancer accounts for nearly one in three new cancer cases among women, and approximately one in eight women in the United States will develop breast cancer during her lifetime.

Association between COVID-19 by variant period and delivery-related outcomes in the United States Deborah Kilday ,Michael Korvink,Drew Tatum,Zhun Cao,Ning Rosenthal,Raymond Perigard,Ashley Finke,Richelle Marshall,Margaret Snyder,Kelly Larson,Alain Moluh,Stephanie Martin,Samantha Sommerness,

https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0355223&utm_medium=email&utm_source=govdelivery OWH Research Examines COVID-19 and Delivery-Related Outcomes Across Variant Periods Study A new study supported by the HHS Office on Women’s Health examined associations between COVID-19 infection and delivery-related outcomes during different COVID-19 variant periods in the United States. Published in PLOS ONE, the study analyzed more than 2.5 million delivery-related hospitalizations from April 2020 through March 2023. More than 53,000 of these hospitalizations involved a COVID-19 diagnosis, providing researchers with data to assess maternal delivery outcomes across multiple phases of the pandemic and variant periods nationwide.